SCHEMBL29927385

SCHEMBL29927385

C[C@H]1CN(C(=O)OCc2ccccc2)CCN1CC1CNC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.58
PDK1 Q15118 1/20 0.53
PDK2 Q15119 1/20 0.53
PDK3 Q15120 1/20 0.53
PDK4 Q16654 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
CYP2C19 P33261 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HTT P42858 1/20 0.44
MMP9 P14780 3/20 0.44
MMP1 P03956 2/20 0.44
MMP3 P08254 2/20 0.44
MMP7 P09237 1/20 0.44
MMP13 P45452 1/20 0.44
CHRM1 P11229 1/20 0.44
OPRK1 P41145 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29928413 0.92 HTR2C (0.51) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL29928438 0.89 HTR2C (0.50) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL4329419 0.83 PDK1 (0.56) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL26924710 0.83 SMN1; SMN2 (0.55) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL26924703 0.83 SMN1; SMN2 (0.55) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL26926920 0.83 SMN1; SMN2 (0.55) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL29927532 0.83 PDK1 (0.52) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL29927520 0.81 PDK1 (0.51) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL30731906 0.81 PDK1 (0.51) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL30706191 0.81 PDK1 (0.51) PDK1PDK2PDK3PDK4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559506-B2 Indazole based compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-24 US disclosed
US-20240360152-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-10-31 US disclosed
US-11981683-B2 Indazole based compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-05-14 US disclosed
EP-4308557-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2024-01-24 EP disclosed
CN-117321046-A Indazole-based compounds and related methods of use 阿维纳斯企业公司 2023-12-29 CN disclosed
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-30 US disclosed
WO-2022198112-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360152-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 HTR2C 1116/4885PDK1 1366/4885PDK2 1007/4885
US-12559506-B2 Indazole based compounds and associated methods of use LRRK2, CRBN, CLK2 HTR2C 627/4885PDK1 2125/4885PDK2 1878/4885
US-11981683-B2 Indazole based compounds and associated methods of use LRRK2, CRBN, MDM2 HTR2C 1116/4885PDK1 1366/4885PDK2 1007/4885
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 HTR2C 1116/4885PDK1 1366/4885PDK2 1007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.